Document:

Exhibit 10.2

 

CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO
AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

Exhibit
A-A

AUGMEDIX
NOTES – STATEMENT OF WORK NO. 2

 

This
Augmedix Notes - Statement of Work No. 2 (“Statement of Work” or “SOW”), effective as of the date
of the last signature below (“SOW Effective Date”), is a supplement to the Master Services Agreement (“Agreement”)
by and between customer, as set forth on the signature line below (“Customer”), and Augmedix Operating Corp. f/k/a
Augmedix, Inc. (“Augmedix”), dated May 20, 2015, and is subject to all of the terms and conditions thereof. To the
extent this Statement of Work is inconsistent with the terms of the Agreement, the terms of the Agreement will prevail. All capitalized
terms used in this Statement of Work and not defined herein shall have the meaning assigned to such terms in the Agreement.

 

		1.	OVERVIEW
                                            AND DEFINITIONS

 

1.1. Authorized
Users. This Statement of Work allows Customer and its Affiliates to onboard as many Authorized Users as mutually agreed upon by the
parties. Customer and its Affiliates may purchase Augmedix Notes for their Authorized Users by signing and submitting an ordering document
to Augmedix pursuant to this Statement of Work (each a “Service Order”). Augmedix shall make Augmedix Notes available
to Customer’s or its Affiliates’ designated Authorized Users under this SOW during the Subscription Term indicated in the
Service Order.

 

1.2. Definitions.
As used in this SOW, all terms not otherwise defined in the Agreement or in this SOW shall have the meanings indicated in Schedule
1: Statement of Work Definitions attached hereto.

 

		2.	PARTIES’
                                            RESPONSIBILITIES

 

2.1. Augmedix
Responsibilities. Pursuant to each Service Order executed hereunder, Augmedix will perform the following Services:

 

2.1.1. Implementation
and Deployment. Augmedix will coordinate and manage the implementation and deployment of Augmedix Notes on an Authorized User-by-Authorized
User basis. During the initial deployment for each Authorized User, Augmedix will provide training to the Authorized User and for one
or more Scribe(s) working with the Authorized User such that such Scribe(s) is/are able to satisfactorily complete and upload notes for
patient visits for the Authorized User’s review and finalization.

 

2.1.2. Augmedix
Notes. Augmedix will provide Augmedix Notes as specified herein and the applicable Service Order. Augmedix will facilitate Scribing
and the pending of patient notes in the Customer’s electronic health record system (collectively “Customer EHR”)
prior to the Authorized Users next clinical shift. Augmedix will ensure that all Scribes comply with the terms and conditions of all
agreements between Customer and third parties relating to the use of the Customer EHR software. Customer may access and use Augmedix
Notes solely for its internal business purposes and such access and use is expressly limited to the number of Authorized Users for which
Customer has paid Fees in accordance with the applicable Service Order.

 

2.1.3. Technology
Maintenance. Augmedix will provide Customer with one (1) Content Capture Device kit per Authorized User during the Subscription Term
of the applicable Service Order. The Content Capture Devices and other hardware or materials provided for the purpose of delivering Augmedix
Notes are owned (or leased) by Augmedix.

 

    1

     

    

 

CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO
AUGMEDIX, INC. IF PUBLICLY DISCLOSED. 

 

2.2. Customer
Responsibilities. Commencing on the SOW Effective Date, Customer will have the following responsibilities:

 

2.2.1. IT,
Telecommunications and Internet Services. Customer acknowledges and agrees that Customer’s and its Authorized Users’
use of Augmedix Notes is dependent upon access to telecommunications and Internet services meeting certain minimal site connectivity
requirements. Except for the Content Capture Device(s) and Software, Customer shall be solely responsible for acquiring and maintaining
all telecommunications, Internet services, and other hardware and software required to access and use Augmedix Notes, including, without
limitation, any and all costs, fees, expenses, and taxes of any kind related to the foregoing. Augmedix shall not be responsible for
any loss or corruption of data, lost communications, or any other loss or damage of any kind arising from any such telecommunications
and Internet services.

 

2.2.2. Access.
At no cost to Augmedix, Customer shall provide Augmedix (and any of its third-party Scribe suppliers) with appropriate access and related
credentials for use of the Customer EHR, and any other required Customer Materials, as necessary for Augmedix to provide Augmedix Notes
to Customer. Customer must provide all credentials and permissions necessary for Augmedix personnel to access the Customer EHR within
two (2) weeks of Augmedix’s written request. If credentials are not provided within two (2) weeks of Augmedix’s written request,
Augmedix cannot guarantee Augmedix Notes Service will commence on schedule and reserves the right to delay an Authorized User’s
Launch Date (as defined in Section 3.2.2 below) until appropriate Customer EHR credentials can be provided.

 

2.2.3. Recording
of Patient Encounters. In order to enable Augmedix Notes, Authorized Users shall be responsible for initiating a recording on the
Content Capture Device at the beginning of each patient-provider encounter and stopping the recording at the conclusion of the visit.
For clarity, Authorized Users shall not record patient-provider encounters in a block of two or more visits; each patient-provider encounter
shall be recorded separately. In the event an Authorized User fails to record each patient-provider encounter separately, Augmedix will
make good faith efforts, but cannot guarantee, that patient notes will be available for review and finalization prior to the next clinic
shift.

 

2.2.4. Patient
Education and Consent. Customer shall: (a) inform each patient, prior to an Authorized User’s use of Augmedix Notes with such
patient, of the function, extent, and purpose of Augmedix Notes and utilization of audio/visual recording by means of the Content Capture
Device in accordance with all applicable laws and regulations; and (b) obtain the patient’s consent, to the extent required under
applicable laws and regulations, for the Authorized User to use Augmedix Notes. Without limiting the foregoing, Customer will provide
patients education materials, including FAQs, provided by Augmedix (“Education Materials”). Customer agrees not to
make any material changes to the Education Materials without Augmedix’s prior written consent.

 

2.2.5. Scheduling.
Fourteen (14) days prior to the Launch Date for an Authorized User and the start of each month thereafter, Customer shall input a daily
schedule for each Authorized User for each day of the following month in Customer’s EHR or other scheduling software (“Daily
Schedule”). The Daily Schedule will be used by Augmedix to staff Scribes for Augmedix Notes. If Customer does not notify Augmedix
fourteen (14) days in advance of clinic, Augmedix cannot guarantee Scribe availability.

 

2.2.5.1 Customer
must provide fourteen (14) days’ written notice in advance of any material Daily Schedule change during a month. If less than fourteen
(14) days’ written notice is received, Augmedix will make good faith efforts, but does not guarantee, to accommodate such requests.

 

    2

     

    

 

CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO
AUGMEDIX, INC. IF PUBLICLY DISCLOSED. 

 

2.2.6. Feedback
and Cooperation. Customer’s Authorized Users shall provide cooperation and feedback to Augmedix and its Scribes as reasonably
requested by Augmedix to fulfill its responsibilities in this Statement of Work.

 

2.3. Software
and Equipment.

 

2.3.1. Software.

 

a) Subject
to the terms and conditions of the Agreement, Augmedix hereby grants Customer a non-exclusive, non-transferable, non-sublicensable right
for Customer and its Authorized Users to (a) access and use Augmedix Notes; (b) use the Software; (c) use, copy, publish, and transmit
the Documentation, solely for Customer’s internal training purposes; and (d) use, copy, publish, transmit, distribute, publicly
display the Education Materials in connection with using Augmedix Notes. For the avoidance of doubt, the Software may be used by Customer
on a concurrent-user basis to the extent necessary for Customer to receive Augmedix Notes for the agreed-upon number of Authorized Users.

 

b) Restrictions.
Without the prior written consent of Augmedix, Customer shall not attempt to interfere with or disrupt Augmedix Notes or the Software
or attempt to gain access to any systems or networks that connect thereto (except as required to access and use Augmedix Notes). Customer
shall not allow access to or use of Augmedix Notes by anyone other than Authorized Users. Customer shall not: (a) copy, modify or distribute
any portion of Augmedix Notes or the Documentation; (b) sell, rent, lease, lend, license, sublicense, distribute, or otherwise transfer
Augmedix Notes or the Documentation to any third party; (c) decompile, disassemble or reverse engineer any portion of Augmedix Notes;
(d) write or develop any derivative software or service based upon Augmedix Notes, the Documentation or any Augmedix Confidential Information;
(e) use Augmedix Notes to provide processing or other services to third parties, or otherwise use Augmedix Notes on a “service
bureau” basis; or (f) provide, disclose, divulge or make available to, or permit use of Augmedix Notes or Documentation by any
third party without Augmedix’s prior written consent.

 

2.3.2. Provision
of Hardware.

 

a) Subject
to Customer’s compliance with this Section 2.3.2, the acquisition, installation, configuration, and maintenance of the Content
Capture Devices, including installation of all updates and other upgrades, will be solely the responsibility of Augmedix.

 

b) Customer
shall ensure that Authorized Users: (a) maintain the Content Capture Devices in good repair, condition and working order; and (b) use
the Content Capture Devices in accordance with the applicable user manual(s) and guidelines provided from time to time by Augmedix. Upon
receipt of a Content Capture Device, Customer shall bear the entire risk of loss, damage, theft, or destruction of the Content Capture
Device or any part thereof, from any and every cause whatsoever, which shall occur prior to the return of the Content Capture Devices
to Augmedix, excluding reasonable wear and tear.

 

c) Customer
shall not: (a) sublease any of the Content Capture Devices; (b) create or incur, or permit to exist, any lien or encumbrance
with respect to any of the Content Capture Device; (c) load any software other than the Software provided by Augmedix onto any Content
Capture Device; (d) disable any protective safeguards; or (e) use the Content Capture Devices outside of the approved Customer Facilities
or for any purposes other than those set forth in this Agreement.

 

d) Upon
the termination or expiration of the Agreement, Customer will disconnect, package and return the Content Capture Devices to Augmedix
in the same condition as when delivered to Customer, ordinary wear and tear excepted. To the extent any Content Capture Device is lost,
stolen or damaged, Augmedix may invoice Customer its reasonable costs for repair or replacement of such Content Capture Device and Customer
shall promptly pay such costs within [***] of receiving such invoice.

 

    3

     

    

 

CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX,
INC. IF PUBLICLY DISCLOSED.

 

		3.	STATEMENT
                                            OF WORK SCHEDULE

 

3.1. Implementation.
Upon execution of each Service Order, Augmedix will perform the following implementation services.

 

3.1.1. Authorized
User Selection. To the extent practicable, Customer’s designated Authorized Users should be identified in the applicable Service
Order. To the extent not identified in a Service Order, Customer shall provide a list of its selected Authorized Users to Augmedix no
later than thirty (30) days prior to the first day Augmedix produces patient notes that are uploaded to the Customer EHR for one or more
Authorized Users. Augmedix will provide rolling guidance on the target Launch Date (as defined in Section 3.2.2. below) for each Authorized
User.

 

3.1.2. Kick-off
Call. Augmedix will initiate and conduct a kick-off call with Customer to collect Authorized Users’ templates, macros and smartsets,
discuss workflow and coordinate appropriate access to the Customer EHR.

 

3.1.3. Technical
Site Evaluation. Augmedix’s Site Connectivity Requirements are set forth on Schedule 2 hereto. To determine whether
Customer’s network infrastructure supports Augmedix Notes, Augmedix will assist remotely with a wireless network assessment on
a mutually agreed upon date. If Augmedix determines Customer’s network infrastructure fails to support Augmedix Notes, Customer
shall be responsible for the cost of any remediation necessary to enable its wireless network infrastructure to support Augmedix Notes.
Alternatively, Augmedix may, subject to a viability assessment and Customer’s approval, deliver Augmedix Notes via LTE mobile technology.

 

3.1.4. Augmedix
Notes Deployment. Augmedix will coordinate and manage the deployment of Augmedix Notes on an Authorized User-by-Authorized User basis.

 

3.2. Service
Phase.

 

3.2.1. The
service phase (“Service Phase”) consists of ongoing non-real time Scribing and pending of patient notes in the Customer
EHR by Augmedix-supplied Scribes on behalf of Customer’s designated Authorized Users.

 

3.2.2. The
Service Phase will commence on the first day Augmedix produces patient notes that are uploaded into the Customer EHR, on an Authorized
User-by-Authorized User basis (each a “Launch Date”), and continue for the remainder of the Subscription Term of the
applicable Service Order.

 

    4

     

    

 

CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO
AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

		4.	FEES
                                            AND EXPENSES; INVOCING

 

4.1. Fees.
In consideration for providing Augmedix Notes, Customer shall pay to Augmedix the Fees for its Subscription, in accordance with the terms
set forth in the applicable Service Order.

 

4.2. Expenses.
To the extent expenses are described in a Service Order, Customer shall reimburse Augmedix for all actual and reasonable expenses incurred
by Augmedix in connection with such Service Order (collectively, “Expenses”).

 

4.3. Invoices;
Payment; Late Payment. Augmedix shall invoice Customer for Fees, Expenses and applicable Taxes in the manner described in the applicable
Service Order. All payments will be made in U.S. dollars. Each undisputed invoice is due and payable by Customer no later than [***]
following the invoice date. If Augmedix has not received payment within [***] after the due date, interest shall accrue on past due amounts
at the rate of [***], but in no event greater than the highest rate of interest allowed by law, calculated from the date such
amount was due until the date that payment is received by Augmedix. Further, if any charge owing by Customer is [***] or more overdue,
Augmedix may, without limiting its other rights and remedies, suspend Services until such amounts are paid in full, provided that, Augmedix
has given Customer at least [***] notice that its account is overdue. 

 

IN
WITNESS WHEREOF, the parties have caused this Statement of Work to be executed and delivered by their respective duly authorized
representatives.

 

	Sutter
    Health	 	Augmedix
    Operating Corp. f/k/a Augmedix, Inc.
	 	 	 
	By:	/s/ Ginny Borncamp	 	By:	/s/ Manny Krakaris, CEO
	Name:   	Ginnay Borncamp	 	Name:  	Manny Krakaris  
	Title: 	VP, Supply Chain	 	Title:	CEO
	Date:	9/11/2021	 	Date:	9/10/2021

 

    5

     

    

 

CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX,
INC. IF PUBLICLY DISCLOSED.

 

Schedule
1

Statement
of Work Definitions

 

(1) “Augmedix
Notes” means the non-real time documentation solution provided by Augmedix to Customer pursuant to a Service Order, which such
solution includes Scribing by remote Scribe(s) for Authorized User(s) from recordings of patient-provider encounters, and the Content
Capture Device(s) and the associated Software.

 

(2) “Authorized
User(s)” means any of the following who are designated in writing to Augmedix as being authorized access to Augmedix Notes
on Customer’s or its Affiliates behalf: (a) employees, students (medical, nursing and other students), volunteers, nurses, physicians
(including referring physicians), medical staff members, and all technicians, clinicians and other personnel and agents on staff or otherwise
associated with Customer and/or its affiliates; (b) third party agents, consultants, system integrators, auditors and other independent
contractors performing services for Customer and/or its affiliates, provided that such individuals and entities are not competitors of
Augmedix and have an agreement with Customer that requires such individuals and entities to comply with terms no less protective of the
Augmedix Notes than those set forth in Section 6 (Confidentiality) of the Agreement; (c) any governmental, accrediting or regulatory
bodies lawfully requesting or requiring access to data; and (d) such other entities as the parties may mutually agree in writing. Authorized
Users are discrete: 1 Authorized User to 1 individual. Multiple individuals may not be “summed” together to create 1 Authorized
User.

 

(3) “Customer
Facility(-ies)” means that certain designated Customer facility or facilities designated in the applicable Service Order.

 

(4) “Content
Capture Device(s)” means that/those certain hardware device(s) provided by Augmedix to Customer’s Authorized Users (e.g.,
smartphone) during the Subscription Term to enable remote, non-real time Scribing on behalf of Customer.

 

(5) “Documentation”
means all materials and documentation provided by Augmedix to Customer, whether in hard copy, magnetic media or machine-readable
form, pertaining to the capabilities, operation, software and/or Services of the Augmedix Notes, as amended and updated by Augmedix from
time to time.

 

(6) “Scribe”
means an Augmedix-supplied individual who performs Scribing on behalf of an Authorized User.

 

(7) “Scribing”
means a Scribe’s act of entering, editing, and/or looking up content in Customer’s EHR and uploading patient notes into the
Customer’s EHR on behalf of an Authorized User based upon a patient-provider encounter, subject to the Authorized User’s
review, finalization and approval.

 

(8) “Software”
means the software supplied by Augmedix pursuant to the applicable Service Order.

 

(9) “Subscription” means
the access to the Augmedix Notes Services purchased by Customer on a per Authorized User basis.

 

(10) “Subscription
Term” means the period identified in the Service Order during which Customer’s Authorized User(s) is/are permitted
to access and use Augmedix Notes on a per Authorized User basis.

 

    6

     

    

 

CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO
AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

 

Schedule
2

Site
Connectivity Requirements

 

	1.	Internet
                                            Service Provider
	 	 

		●	Cable
or Fiber internet connectivity
	 	 	 

	2.	Wireless
Infrastructure
	 	 

		●	Access
Point (AP) model offers 802.11n or greater

		●	WPA2
                                            PSK (AES) or WPA2 PEAP authentication

		●	PMK
                                            Key Caching enabled (CCKM also acceptable)

		●	DHCP
                                            required
	 	 	 

	3.	Firewall
Services and Ports
	 	 

Enable
on the firewall, all outbound originated Augmedix network traffic, the requirements of which will be provided by Augmedix separately.

 

 

7Exhibit 10.1

 

EMPLOYMENT
AGREEMENT

 

EMPLOYMENT AGREEMENT
(this “Agreement”), dated as of _9/12/21_ by and between STAGWELL INC., and its affiliates (the “Company”),
and JAY LEVETON (the “Executive”).

 

W
I T N E S S E T H:

 

WHEREAS,
the Company wishes to employ the Executive, and the Executive wishes to accept such employment, upon the terms and conditions hereinafter
set forth.

 

NOW, THEREFORE,
in consideration of the premises and other good and valuable consideration, receipt of which is hereby acknowledged, the parties hereto
agree as follows:

 

		1.	Employment

 

The Company agrees
to employ the Executive during the Term specified in Section 2, and the Executive agrees to accept such employment, upon the terms
and conditions hereinafter set forth.

 

		2.	Term

 

Subject to the provisions
contained in Sections 6 and 7, the Executive’s employment by the Company shall be for a term (the “Term”) commencing
as soon as practicable as mutually agreed between the Company and the Executive and as approved by the Compensation Committee of Stagwell
Inc.’s Board of Directors (the “Board”), but not later than September 1, 2021 (the “Commencement Date”),
and continuing for an indefinite period thereafter unless and until (i) the Executive delivers to the Company ninety (90) days’
advance written notice of resignation (a “Notice of Termination”) (ii) the Company terminates the Executive’s employment
with or without “Cause” (as defined herein) or (iii) the Agreement is terminated due to Executive’s death or “Disability”
(as defined herein). Any Notice of Termination given by the Executive under this Section 2 shall specify the date of termination and the
fact that the notice is being delivered pursuant to Section 2 of this Agreement. In the event that the Executive delivers a Notice of
Termination, the Company shall have the right to either (i) waive all or part of such ninety (90)-day notice period or (ii) at any time
during such ninety (90)-day notice period to relieve the Executive of all or any portion of his offices, duties and responsibilities and
place him on a paid leave-of-absence status. The date on which the Executive ceases to be employed by the Company, regardless of the reason
therefor, is referred to in this Agreement as the “Termination Date”.

 

		3.	Duties and Responsibilities

 

(a)                 Title. During the Term, the Executive shall have the position of President, or such other leadership title as the Chief Executive
Officer of the Company may designate.

 

(b)                 Duties.
The Executive shall report directly to the Chief Executive Officer of

 

    1 

     

    

 

(c)                
the Company or his designee. The Executive is responsible for managing individual networks, working closely with the CEOs of the companies
and the networks on a day-to-day basis. The Executive shall set incentives and be responsible for the CEOs and companies working together
to grow the overall business. The Executive shall work with the Chief Financial Officer and the Chief Operating Officer to help implement
cost control programs and shall work with the Chief Brand Officer to implement the Company’s new brand image. The Executive also
shall perform such executive and managerial duties and responsibilities customary to his office and as are reasonably necessary to the
operations of the Company. The Chief Executive Officer may direct or require the Executive to undertake other or different leadership
duties if in the reasonable judgment of the Chief Executive Officer such duties are in the best interests of the Company.

 

(d)                 Responsibilities; Scope of Employment. The Executive’s employment by the Company shall be full-time and exclusive, except
as noted in this Agreement, and during the Term, the Executive agrees that he will (i) devote all of his business time and attention,
his best efforts, and all his skill and ability to promote the interests of the Company, and (ii) carry out his duties in a competent
manner and serve the Company faithfully and diligently under the direction of the Chief Executive Officer. Notwithstanding the foregoing,
the Company acknowledges and agrees that Executive may continue to receive carried interest from Executive’s contractual arrangement
with Stagwell Group Holdings and such contractual arrangement for carried interest or other passive investment therein in no way violates
the terms of this Agreement. Additionally, Executive shall be permitted to engage in to manage his personal passive investments, provided
that such passive investments are not in a company which transacts business with the Company or engages in business competitive with that
conducted by the Company (or, if such company does transact business with the Company, or does engage in a competitive business, it is
a publicly held corporation and the Executive’s participation is limited to owning less than 1% of its outstanding shares), excepting
and further provided that any such activities, individually or in the aggregate, do not interfere with the performance of his duties or
responsibilities under this Agreement.

 

(e)                 Office
Location. During the Term, the Executive’s services hereunder shall be performed at the offices of the Company in Washington,
DC, subject to necessary travel requirements in order to carry out his duties in connection with his position hereunder.

 

		4.	Compensation

 

(a)                 Base
Salary. As compensation for his services hereunder, during the Term, the Company shall pay the Executive, in accordance with its
normal payroll practices, an annualized base salary of $725,000, which may be increased from time to time by the Board, subject to customary
withholding for federal, state and local taxes (such annualized base salary, as it may be so increased, “Base Salary”).

 

(b)                 Annual
Discretionary Bonus Eligibility. During the Term, the Executive will be eligible to receive an annual discretionary bonus in a target
amount equal to 80% of his Base Salary, which target amount may be increased from time to time by the Board. The annual discretionary
bonus shall be based upon criteria determined by the Chief Executive Officer and the Compensation Committee of the Board, which criteria
will include the Executive’s performance, the overall financial performance of the Company, and such other factors as the Chief
Executive Officer and the Compensation Committee deem reasonable and appropriate in their discretion (such annual discretionary bonus,
as it may be so increased, the “Annual Discretionary Bonus”). The Annual Discretionary Bonus will be paid in accordance
with the Company’s normal bonus payment procedures, subject to customary withholding for federal, state, and local taxes. The Annual
Discretionary Bonus for 2021 (the “2021 Bonus”) will be pro-rated by one-half, with July 1, 2021 as the start date
of Executive’s eligibility period for the 2021 Bonus.

 

    2 

     

    

 

(c)                 Grants
under LTIP Plans. The Executive shall be eligible to participate in the Company’s long-term incentive plans with a target value
and metrics as determined the Chief Executive Officer and the Compensation Committee of the Board. The Company anticipates that the LTIP
grants will be determined in 2022, reflective of Executive’s work in 2021.

 

(d)                 Initial
Cash Bonus Award. The Company shall pay the Executive a one-time bonus in an amount equal to $325,000
(the “Signing Bonus”) within thirty (30) days after the Commencement Date, subject to applicable withholding
for federal, state, and local taxes. Notwithstanding the foregoing, in the event the Executive resigns or is terminated by the Company
for “Cause” within six (6) months of the Commencement Date, you shall immediately pay back to to the Company an amount equal
to the full amount of the Signing Bonus.

 

		5.	Business and Professional Expenses; Health and Welfare Benefits

 

(a)                 Expenses. During the Term, the Company agrees to pay or to reimburse the Executive for all reasonable, ordinary, necessary, and
documented business or entertainment expenses incurred in the performance of his services hereunder. The Executive, as a condition precedent
to obtaining such payment or reimbursement, shall provide to the Company any and all statements, bills or receipts evidencing the travel
or out-of-pocket expenses for which the Executive seeks payment or reimbursement, and any other information or materials, as the Company
may from time to time reasonably require.

 

(b)                 Benefit
Plans. During the Term, the Executive and, to the extent eligible, his dependents, shall be entitled to participate in and receive
all benefits under any group health plans, welfare benefit plans and programs (including without limitation, medical, medical reimbursement,
disability, and group life insurance) provided by the Company to its senior executives generally, subject to the generally applicable
eligibility and other provisions of the various plans and programs in effect from time to time.

 

(c)                 Vacation.
The Executive shall be entitled to twenty (20) days of vacation in accordance with the Company’s policies, with no right of carry
over, to be taken at such times as shall not materially interfere with the Executive’s fulfillment of his duties hereunder.

 

		6.	Termination

 

(a)                 Termination for Cause. The Company, by direction of the Board or the Chief Executive Officer, shall be entitled to terminate the Term
and to discharge the Executive for Cause effective upon the giving of written notice. The term “Cause” shall be limited
to the following grounds:

 

    3 

     

    

 

(i)                 
the Executive's failure or refusal to perform his duties and responsibilities as set forth in Section 3 hereof, or abide by the
reasonable directives of the Chief Executive Officer or the Board, or the failure of the Executive to devote all of his business time
and attention exclusively to the business and affairs of the Company in accordance with the terms hereof, in each case following written
notice to the Executive from the Chief Executive Officer or the Board specifying such failure and that it may be deemed to be Cause and
a five (5) business day period to perform or cure (if curable);

 

(ii)                
the willful misappropriation of the funds or property of the Company;

 

(iii)              
the use of alcohol or illegal drugs, materially interfering with the performance of the Executive’s obligations under this Agreement,
continuing after written warning contained in a notice;

 

(iv)              
the conviction in a court of law of, or entering a plea of guilty or no contest to, any felony or any crime involving moral turpitude,
dishonesty or theft;

 

(v)               
the material nonconformance with the Company’s standard business practices and policies, including without limitation, policies
against racial or sexual discrimination or harassment, made known to the Executive, which nonconformance is not cured (if curable) within
two (2) days after written notice to the Executive by the Company;

 

(vi)              
the commission in bad faith by the Executive of any act which materially injures or could reasonably be expected to materially injure
the reputation, business or business relationships of the Company or any subsidiary;

 

(vii)             
the gross or habitual misconduct or gross or habitual negligence by the Executive in the performance of his duties which misconduct or
negligence is not cured (if curable) within five (5) business days after written notice to the Executive by the Company; and

 

(viii)            
any material breach (not covered by any of the clauses (i) through (vii) above) of any material term of this Agreement, if such breach
is not cured (if curable) within five (5) business days after written notice thereof to the Executive by the Company.

 

Any notice required to be given by
the Company pursuant to any of the clauses above shall specify the specific nature of the claimed breach and the manner in which the Company
requires such breach to be cured (if curable). In the event that the Executive is purportedly terminated for Cause and a court determines
that Cause as defined herein was not present, then such purported termination for Cause shall be deemed a termination without Cause pursuant
to Section 6(b) and the Executive’s rights and remedies will be governed by Section 7(b), in full satisfaction and
in lieu of any and all other or further remedies the Executive may have under this Agreement.

 

    4 

     

    

 

(b)                
Termination without Cause. The Company, by direction of the Board or the Chief Executive Officer, shall have the right at any time
to immediately terminate the Term and the employment of the Executive without Cause by giving written notice to the Executive.

 

(c)                  Termination
for Death or Disability. In the event of the Executive’s death, the Termination Date shall be the date of the Executive’s
death. In the event that (i) the Executive shall be unable to perform his duties hereunder by virtue of illness or physical or mental
incapacity or disability (from any cause or causes whatsoever) in substantially the manner and to the extent required hereunder prior
to the commencement of such disability and (ii) the Executive shall fail to perform such duties for periods aggregating 120 days, whether
or not continuous, in any continuous period of 365 days (all such causes being herein referred to as “Disability”),
the Company shall have the right to terminate the Executive’s employment hereunder as at the end of any calendar month during the
continuance of such Disability upon prior written notice to him.

 

		7.	Effect of Termination of Employment

 

(a)                 Termination
by the Company for Cause; or pursuant to a Notice of Termination given by the Executive. In the event of the termination of the employment
of the Executive (1) by the Company for Cause, or (2) by the giving of a Notice of Termination under Section 2 hereof by the Executive,
the Executive shall be entitled to unpaid Base Salary through, and any unpaid reimbursable expenses outstanding as of, the Termination
Date (the “Accrued Rights”), and, except as provided in this Section 7(a) and such rights granted by the Consolidated
Omnibus Budget Reconciliation Act (“COBRA”), the Company shall have no further liability to the Executive or the Executive’s
heirs, beneficiaries or estate for damages, compensation, benefits, severance, indemnities or other amounts of whatever nature, directly
or indirectly, arising out of or otherwise related to this Agreement and the Executive’s employment or cessation of employment
with the Company.

 

(b)                 Termination of the Executive’s Employment without Cause. In the event of a termination of the Executive’s employment
without Cause, the Executive shall be entitled to the following payments:

 

(i)                 
The Accrued Rights as provided in Section 7(a) hereof; and

 

(ii)                
his applicable Base Salary compensation when otherwise payable for a period commencing on the Termination Date and ending on the end of
the six (6)-month period immediately following the Termination Date (the “Severance Period”). The severance amount
described in this Section 7(b)(ii), less applicable withholding of any tax amounts, shall be paid by the Company to the Executive over
the Severance Period in accordance with the Company’s customary payroll practices; provided that the first payment shall be made
on the Company’s first normal payroll date following the 60th day following the Date of Termination, and any payments
that would otherwise have been payable prior to such payroll date shall be paid in a lump sum on such payroll date.

 

    5 

     

    

 

In
connection with a termination by the Company without Cause, except as provided in this Section 7(b) and the rights granted by
COBRA, the Company shall have no further liability to the Executive or the Executive’s heirs, beneficiaries or estate for
damages, compensation, benefits, severance, indemnities or other amounts of whatever nature, directly or indirectly, arising out of
or otherwise related to this Agreement and the Executive’s employment or cessation of employment with the Company. The
Executive shall be under no duty to mitigate damages hereunder; provided, however, in the event that the Executive
obtains any other employment or consulting arrangement, he shall promptly notify the Company, and any compensation and benefits paid
to the Executive therefrom shall reduce the Company’s severance obligations under this Section 7(b). From time to time
during the Severance Period, upon the Company’s reasonable written request, the Executive shall provide the Company with
written verification (such as wage stubs, tax returns and new employer verifications) of amounts earned from such other employment
or consulting arrangements, as well as when and if he is entitled to receive coverage under the benefit plans of any new employer in
which he participates. In the event the Executive fails to supply such information within twenty (20) days following a written
request by the Company, the obligations of the Company under this Section 7(b) shall terminate. The making of any severance
payments and providing the other benefits as provided in this Section 7(b) is conditioned upon the Executive signing,
complying with and not revoking a separation agreement and general release approved by the Company, and such release becoming
effective and irrevocable within 60 days following the Termination Date. In the event the Executive breaches any material provisions
of the separation agreement or any of the provisions of Section 8 of this Agreement, which breach is not cured (if curable)
within any applicable cure period, in addition to any other remedies at law or in equity available to it, the Company may cease
making any further payments and providing the other benefits provided for in this Section 7(b), without affecting its rights
under this Agreement or the separation agreement and general release.

 

(c)                 Termination
by Death or Disability. In the event of the termination of the employment of the Executive by reason of death or Disability, the
Executive (or, as applicable, his estate or personal representative) shall be entitled to unpaid Base Salary through, and any unpaid
reimbursable expenses outstanding as of, the Termination Date. In the event of the termination of the employment of the Executive by
reason of death or Disability, except as provided in this Section 7(c) and such rights granted by COBRA, the Company shall have
no further liability to the Executive or the Executive’s heirs, beneficiaries or estate for damages, compensation, benefits, severance,
indemnities or other amounts of whatever nature, directly or indirectly, arising out of or otherwise related to this Agreement and the
Executive’s employment or cessation of employment with the Company.

 

		8.	Protective Covenants and Protection of Confidential Information

 

(a)                 Definitions. As used in this Section 8, the following terms shall have the meanings set forth below:

 

(i)                
 “Company” means Stagwell Inc. and each of its subsidiaries.

 

(ii)               
 “Client” means any Person (as defined below) to whom, at any time during the period that the Executive was in the employ
of the Company, the Company (x) rendered services or (y) made a Pitch.

 

(iii)             
 “Person” means and includes an individual, a company, a joint venture, a corporation (including any non-profit
corporation), an estate, an association, a trust, a general or limited partnership, a limited liability company, a limited liability
partnership, an unincorporated organization and a government or other department or agency thereof.

 

    6 

     

    

 

(iv)             
 “Pitch” means a new business presentation or similar offering of services; provided, however, a general
mailing or an incidental contact shall not be deemed a Pitch.

 

(v)               
 “Post-Employment Restriction Period” means the period of time commencing on the Termination Date and continuing until
the end of the twenty- four (24) month period following the Termination Date. For greater clarity, the Post-Employment Restriction Period
shall commence at the end of the ninety (90)- day notice period referred to in Section 2 of this Agreement in the event that a
Notice of Termination is delivered pursuant to Section 2 of this Agreement.

 

(vi)             
 “Restricted Client” means (x) anyone who was a Client of the Company on the Termination Date or at any time during
the one-year period immediately preceding the Termination Date, and (y) any prospective Client to whom the Company made a Pitch at any
time during the one-year period prior to, or the six month period immediately following, the Termination Date, but with respect to any
Pitch made after the Termination Date, only if the Executive participated in or had a supervisory responsibility or other involvement
in the discussions with the potential Client preceding the Pitch and/or participated in the preparation of the Pitch and/or the actual
Pitch. In addition, if the Restricted Client is part of a group of companies which conducts business through more than one entity, division
or operating unit, whether or not separately incorporated (a “Client Group”), the term “Restricted Client”
as used herein shall include each entity, division and operating unit of the Client Group where the same management group of the Client
Group has the decision making authority or significant influence with respect to contracting for services of the type rendered by the
Company.

 

(vii)           
 “Restricted Business” means the business of any advertising, marketing, digital (non-technology) or communication services.

 

(viii)          
 “Restricted Territory” means the United States and any other geographic area in which the Company or any of its controlled
subsidiaries or managerially controlled affiliates render services to its Clients.

 

(b)                 Restrictions
on Certain Activities. The Executive acknowledges (i) that the business and the industry in which the Company competes is highly
competitive; (ii) that as a key executive of the Company whose responsibilities and duties require is involvement in all aspects of
the business of the Company, he may participate in the servicing of Clients and/or the solicitation of prospective clients, through
which, among other things, the Executive has obtained and will continue to obtain knowledge of the “know-how” and
business practices of the Company, in which matters the Company has a substantial proprietary interest; (iii) that his employment
hereunder requires the performance of services which are special, unique, extraordinary and intellectual in character, and his
senior position with the Company places him in a position of confidence and trust with the Clients and employees of the Company;
(iv) that as a key executive of the Company he has participated in and will continue to participate in the solicitation and hiring
of executives and other employees of the Company and that his senior position with the Company has put him, and will put him in a
position of becoming very familiar with the talents, needs, capabilities and characteristics of such employees and executives; and
(v) that his rendering of services to the Clients and his supervisory responsibilities involving employees of the Company
necessarily required and will continue to require the disclosure to the Executive of Confidential Information (as defined in Section
8(c) hereof) of the Company. In the course of the Executive’s employment with the Company, the Executive may develop a
personal relationship with the Clients of the Company and a knowledge of those Clients’ affairs and requirements, and the
relationship of the Company with its established clientele will therefore be placed in the Executive’s hands in confidence and
trust. The Executive consequently acknowledges that it is a legitimate interest of the Company, and reasonable and necessary for the
protection of the Confidential Information, goodwill and business of the Company, which is valuable to the Company, that the
Executive make the covenants contained herein and that the Company would not have entered into this Agreement unless the covenants
set forth in this Section 8 were contained in this Agreement. Accordingly, except as acknowledged below, the Executive agrees that
he will not, as an individual, employee, consultant, independent contractor, partner, shareholder, member or in association with any
other Person, except on behalf of the Company, directly or indirectly, and regardless of the Executive continuing to be employed by
the Company, or the reason for the Executive ceasing to be so employed by the Company:

 

    7 

     

    

 

(i)                 
during the Term and continuing until the end of the Severance Period, solicit business on behalf of, render any competitive services to,
engage in, guaranty any obligations of, extend credit to, or have any ownership interest or other affiliation in, any business or other
endeavor, which is engaged in the Restricted Business in the Restricted Territory; provided, however, that nothing contained
in this clause (i) shall be deemed to prevent the undersigned from owning less than 1% of the shares of any publicly held corporation
engaged in any such business or from any other rights granted in this Agreement;

 

(ii)               
during the Post-Employment Restriction Period, in the Restricted Territory, solicit, render services to or for, or accept from, anyone
who is a Restricted Client, any Restricted Business of the type performed by the Company, or persuade or attempt in any manner to persuade
any Restricted Client to cease to do any business of the type performed by the Company or to reduce the amount of business which any such
Restricted Client has customarily done or is reasonably expected to do with the Company, whether or not the relationship between the Company
and such Restricted Client was originally established in whole or in part through the Executive’s efforts;

 

(iii)             
during the Post-Employment Restriction Period, be employed in the Restricted Territory by a Restricted Client to solicit or render services
of the type performed by the Company for such Restricted Client without prior written approval by the Company (the determination of which
shall not be unreasonably delayed); or

 

    8 

     

    

 

(iv)             
during the Post-Employment Restriction Period, employ as an employee or retain as a consultant, any individual who is then or at any time
during the one-year period prior to the Termination Date was, an employee of or exclusive consultant to, the Company, or, persuade or
attempt to persuade any employee of or exclusive consultant to the Company to leave the employ of the Company or to become employed as
an employee or retained as a consultant by any other Person without prior written approval by the Company.

 

(c)                 Confidential
Information. In the course of the Executive’s employment with the Company, he will acquire and have access to confidential
or proprietary information about the Company and/or its clients, including but not limited to, trade secrets, methods, models, passwords,
access to computer files, financial information and records, computer software programs, agreements and/or contracts between the Company
and its clients, client contacts, client preferences, creative policies and ideas, advertising campaigns, creative and media materials,
graphic design materials, sales promotions and campaigns, sales presentation materials, budgets, practices, concepts, strategies, methods
of operation, financial or business projections of the Company and information about or received from clients and other companies with
which the Company does business. The foregoing shall be collectively referred to as “confidential information”. The
Executive is aware that the confidential information is not readily available to the public and accordingly, the Executive also agrees
that he will not at any time (whether during the Term or after termination of this Agreement) disclose to anyone (other than his counsel
in the course of a dispute arising from the alleged disclosure of confidential information or as required by law) any confidential information,
or utilize such confidential information for his own benefit, or for the benefit of third parties. The Executive agrees that the foregoing
restrictions shall apply whether or not any such information is marked “confidential” and regardless of the form of the information.
The term “confidential information” does not include information which (i) is or becomes generally available to the public
other than by breach of this provision or (ii) the Executive learns from a third party who is not under an obligation of confidence to
the Company or a client of the Company. In the event that the Executive becomes legally required to disclose any confidential information,
he will provide the Company with prompt notice thereof so that the Company may seek a protective order or other appropriate remedy and/or
waive compliance with the provisions of this Section 8(b) to permit a particular disclosure. In the event that such protective
order or other remedy is not obtained, or that the Company waives compliance with the provisions of this Section 8(b) to permit
a particular disclosure, the Executive will furnish only that portion of the confidential information which he is legally required to
disclose and, at the Company’s expense, will cooperate with the efforts of the Company to obtain a protective order or other reliable
assurance that confidential treatment will be accorded the confidential information. The Executive further agrees that all memoranda,
disks, files, notes, records or other documents, whether in electronic form or hard copy (collectively, the “material”)
compiled by him or made available to him during his employment with the Company (whether or not the material constitutes or contains
confidential information), and in connection with the performance of his duties hereunder, shall be the property of the Company and shall
be delivered to the Company on the termination of the Executive’s employment with the Company or at any other time upon request.
Except in connection with the Executive’s employment with the Company, the Executive agrees that he will not make or retain copies
or excerpts of the material, provided that the Executive shall be entitled to retain his personal files.

 

    9 

     

    

 

Nothing
in this Agreement shall prohibit or impede the Executive from communicating, cooperating or filing a complaint with any U.S.
federal, state or local governmental or law enforcement branch, agency or entity (collectively, a “Governmental
Entity”) with respect to possible violations of any U.S. federal, state or local law or regulation, or otherwise making
disclosures to any Governmental Entity, in each case, that are protected under the whistleblower provisions of any such law or
regulation, provided that in each case such communications and disclosures are consistent with applicable law. The Executive
understands and acknowledges that an individual shall not be held criminally or civilly liable under any federal or state trade
secret law for the disclosure of a trade secret that is made (x) in confidence to a federal, state, or local government official or
to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (y) in a complaint or other
document filed in a lawsuit or other proceeding, if such filing is made under seal. The Executive understands and acknowledges
further that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may
disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the
individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to
court order. For purposes of this Agreement, each of the foregoing communications or disclosures is a “Protected
Disclosure”. The Executive does not need to give prior notice to (or get authorization from) the Company regarding any
Protected Disclosure. Except as otherwise provided in this Section 8(b) or under applicable law, notwithstanding the
foregoing, under no circumstance will the Executive be authorized to disclose any information covered by attorney- client privilege
or attorney work product of the Company, or the Company’s trade secrets, without prior written consent of the Company’s
General Counsel or other officer designated by the Company.

 

(d)                     
Remedies; Acknowledgments. If the Executive commits or threatens to commit a breach of any of the provisions of Sections 8(a)
or (b), the Company shall have the right to have the provisions of this Agreement specifically enforced by any court having jurisdiction
without being required to post bond or other security and without having to prove the inadequacy of the available remedies at law, it
being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Company and that money damages
will not provide an adequate remedy to the Company. In addition, the Company may take all such other actions and remedies available to
it under law or in equity and shall be entitled to such damages as it can show it has sustained by reason of such breach.

 

The
parties acknowledge that (i) the type and periods of restriction imposed in the provisions of Sections 8(a) and (b)
are fair and reasonable and are reasonably required in order to protect and maintain the proprietary interests of the Company
described above, other legitimate business interests and the goodwill associated with the business of the Company; (ii) the time,
scope and other provisions of this Section 8 have been specifically negotiated by sophisticated parties, represented by legal
counsel, and are given as an integral part of the transactions contemplated by this Agreement; and (iii) because of the nature of
the business engaged in by the Company and the fact that clients can be and are serviced by the Company wherever they are located,
it is impractical and unreasonable to place a geographic limitation on the agreements made by the Executive herein. The Executive
specifically acknowledges that his being restricted from soliciting and servicing Restricted Clients as contemplated by this
Agreement will not prevent him from being employed or earning a livelihood in the type of business conducted by the Company. If any
of the covenants contained in Sections 8(a) and (b), or any part thereof, is held to be unenforceable by reason of it
extending for too great a period of time or over too great a geographic area or by reason of it being too extensive in any other
respect, the parties agree (x) such covenant shall be interpreted to extend only over the maximum period of time for which it may be
enforceable and/or over the maximum geographic areas as to which it may be enforceable and/or over the maximum extent in all other
respects as to which it may be enforceable, all as determined by the court making such determination and (y) in its reduced form,
such covenant shall then be enforceable, but such reduced form of covenant shall only apply with respect to the operation of such
covenant in the particular jurisdiction in or for which such adjudication is made. Each of the covenants and agreements contained in
this Section 8 (collectively, the “Protective Covenants”) is separate, distinct and severable. All rights,
remedies and benefits expressly provided for in this Agreement are cumulative and are not exclusive of any rights, remedies or
benefits provided for by law or in this Agreement, and the exercise of any remedy by a party hereto shall not be deemed an election
to the exclusion of any other remedy (any such claim by the other party being hereby waived). The existence of any claim, demand,
action or cause of action of the Executive against the Company, whether predicated on this Agreement or otherwise, shall not
constitute a defense to the enforcement by the Company of each Protective Covenant. The unenforceability of any Protective Covenant
shall not affect the validity or enforceability of any other Protective Covenant or any other provision or provisions of this
Agreement.

 

    10 

     

    

 

(e)                 Notification
of Restrictive Covenants. Prior to accepting employment with any person, firm or entity during the Post-Employment Restriction Period,
the Executive shall notify the prospective employer in writing of his obligations pursuant to this Section 8 (it being agreed
by the Company that such notification required under this Section 8(e) shall not be deemed a breach of the confidentiality provisions
of this Agreement). Executive may provide a copy of the provisions of this Section 8 to any such prospective employer.

 

(f)                  Tolling.
The temporal duration of the covenants set forth in Section 8 of this Agreement shall not expire, and shall be tolled, during
any period in which the Executive is in violation of any such covenants, and all restrictions shall automatically be extended by the
period of the Executive’s violation of any such restrictions.

 

		9.	Intellectual Property

 

The Executive agrees
that all materials created or modified by him during the Term, including, without limitation, all works of authorship, inventions, processes,
ideas, methods, concepts and other tangible and intangible materials (collectively, “Work Product”), shall be “work
for hire” and that the Company shall be the exclusive owner of the Work Product and all intellectual property rights associated
with the Work Product, including all trademarks, patents or copyrights contained therein. To the extent any Work Product does not qualify
as “work for hire”, the Executive hereby assigns ownership of all such Work Product to the Company and agrees to take all
reasonable measures, at the Company’s expense, to perfect such rights in the Company. The Executive hereby appoints the Company
as his attorney-in-fact with the limited power to execute assignments of such Work Product.

 

		10.	Enforceability

 

The
failure of any party at any time to require performance by another party of any provision hereunder shall in no way affect the right
of that party thereafter to enforce the same, nor shall it affect any other party’s right to enforce the same, or to enforce
any of the other provisions in this Agreement; nor shall the waiver by any party of the breach of any provision hereof be taken or
held to be a waiver of any subsequent breach of such provision or as a waiver of the provision itself.

 

    11 

     

    

 

		11.	Assignment

 

The Company and
the Executive agree that the Company shall have the right to assign this Agreement, and, accordingly, this Agreement shall inure to the
benefit of, and may be enforced by, any and all successors and assigns of the Company and/or its business, including, without limitation,
by asset assignment, stock sale, merger, consolidation or other corporate reorganization. The Company and Executive agree that Executive’s
rights and obligations under this Agreement are personal to the Executive, and the Executive shall not have the right to assign or otherwise
transfer his rights or obligations under this Agreement. The rights and obligations of the Company hereunder shall be binding upon and
run in favor of the successors and assigns of the Company.

 

		12.	Modification

 

This Agreement may
not be orally canceled, changed, modified or amended, and no cancellation, change, modification or amendment shall be effective or binding,
unless in writing and signed by the parties to this Agreement.

 

		13.	Severability; Survival

 

In the event any
provision or portion of this Agreement is determined to be invalid or unenforceable for any reason, in whole or in part, the remaining
provisions of this Agreement shall nevertheless be binding upon the parties with the same effect as though the invalid or unenforceable
part had been severed and deleted or reformed to be enforceable. The respective rights and obligations of the parties hereunder (including,
but not limited to those contained in Section 8) shall survive the termination of the Executive’s employment, the Term and
the termination of this Agreement to the extent necessary to the intended preservation of such rights and obligations.

 

		14.	Notice

 

Any notice, request,
instruction or other document to be given hereunder by any party hereto to another party shall be in writing and shall be deemed effective
(a) upon personal delivery, if delivered by hand, or (b) three days after the date of deposit in the mails, sent certified or registered
mail, postage prepaid and return receipt requested, or (c) on the next business day, if sent by prepaid overnight courier service or facsimile
transmission or electronic mail (if electronically confirmed), and in each case, addressed as follows:

 

If to the Executive:

 

Jay Leveton

[ADDRESS]

 

If to the Company:

 

Stagwell Inc.

One World Trade Center, Floor
65

New York, NY 10007

Attn: Legal

 

Any party may change
the address to which notices are to be sent by giving notice of such change of address to the other party in the manner herein provided
for giving notice.

 

    12 

     

    

 

		15.	No Conflict

 

The Executive represents
and warrants that he is not subject to any agreement, instrument, order, judgment or decree of any kind, or any other restrictive agreement
of any character, which would prevent him from entering into this Agreement or which would be breached by the Executive upon his performance
of his duties pursuant to this Agreement.

 

		16.	Entire Agreement; Applicable Law

 

This Agreement and
the documents referenced herein represent the entire agreement between the Company and the Executive with respect to the employment of
the Executive by the Company. This Agreement shall be governed by, enforced under, and construed in accordance with the laws of the State
of New York applicable therein.

 

		17.	Counterparts

 

This Agreement may
be executed in one or more counterparts, and each such counterpart shall be deemed an original instrument, but all such counterparts taken
together shall constitute but one agreement. Facsimile and pdf signatures shall constitute an original.

 

    13 

     

    

 

		18.	409A Compliance

 

This
Agreement is intended to comply, to the extent applicable, with Section 409A of the Internal Revenue Code of 1986, as amended (the
 “Code”) and will be so interpreted. For purposes of this Agreement, a termination of Executive’s services on the
Termination Date shall be determined in a manner consistent with the rules relating to “separation from service” within
the meaning of Section 409A of the Code and the regulations thereunder, if necessary in order to prevent the imposition of any
accelerated or additional tax under Section 409A of the Code. Notwithstanding anything herein to the contrary, (i) if on the
Termination Date Executive is a “specified employee” as defined in Section 409A of the Code, and the deferral of the
commencement of any payments or benefits otherwise payable hereunder as a result of such termination the Agreement is necessary in
order to prevent the imposition of any accelerated or additional tax under Section 409A of the Code, then the Company will (A) defer
the commencement of the payment of any such payments or benefits hereunder (without any reduction in such payments or benefits
ultimately paid or provided to Executive) until the date that is six months following the Termination Date (or the earliest date as
is permitted under Section 409A of the Code), and (B) add to such payment or benefit an interest payment for the six-month period
calculated using the short-term Applicable Federal Rate (monthly compounded) as in effect on the Termination Date under Section
1274(d) of the Internal Revenue Code and (ii) if any other payments of money or other benefits due to the Executive hereunder could
cause the application of an accelerated or additional tax under Section 409A of the Code, the parties agree to restructure the
payments or benefits to comply with Section 409A of the Code in a manner which does not diminish the value of such payments and
benefits to the Executive. To the extent any reimbursements or in-kind benefits due to the Executive under this Agreement constitute
 “deferred compensation” under Section 409A of the Code, any such reimbursements or in-kind benefits shall be paid in a
manner consistent with Treas. Reg. Section 1.409A-3(i)(1)(iv). If under this Agreement, an amount is paid in two or more
installments, each installment shall be treated as a “separate payment” within the meaning of 409A of the Code.

 

* * *

 

    14 

     

    

 

IN WITNESS
WHEREOF, the parties have executed this Agreement as of day and year first above written.

 

	 	STAGWELL INC.
	 	 
	 	By:	/s/	 Mark Penn
	 	Name: 	Mark Penn
	 	Title: 	CEO
	 	 
	 	JAY LEVETON
	 	 
	 	/s/ Jay Leveton

 

    15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]